E-Therapeutics PLC banner

E-Therapeutics PLC
F:3AQ

Watchlist Manager
E-Therapeutics PLC Logo
E-Therapeutics PLC
F:3AQ
Watchlist
Price: 0.091 EUR Market Closed
Market Cap: €53.2m

Wall St Price Targets

3AQ Price Targets Summary
E-Therapeutics PLC

There are no price targets for 3AQ.
Lowest Forecast
Price Target
Not Available
Average Forecast
Price Target
Not Available
Highest Forecast
Price Target
Not Available
E-Therapeutics PLC Competitors:
Price Targets
SHLS
Shoals Technologies Group Inc
34% Upside
INBK
First Internet Bancorp
5% Upside

Revenue
Forecast

15% / Year
Past Growth
8% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
15% / Year
Past Growth
8% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 14 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 1 year is 8%.

Gross Profit
Forecast

16% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
16% / Year
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Gross Profit Forecast
is not available for E-Therapeutics PLC

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-9%
Average Miss

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Pre-Tax Income Forecast
is not available for E-Therapeutics PLC

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
Net Income Forecast
is not available for E-Therapeutics PLC
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is 3AQ's stock price target?
Not Available

3AQ does not have any price targets made by Wall Street professionals.

What is the Revenue forecast for E-Therapeutics PLC?
Projected CAGR
8%

Over the last 14 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 1 year is 8%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett